Deep Intelligence Across Industries

Company Headquarters: Nevada, US Founded: 2010 Workforce: ~100 Company Working: CV Sciences, Inc. is a manufacturer of safe, high-quality, and effective CBD oil products. The company is focusing on promoting healthy living through its pharmaceutical drug development efforts and portfolio of finished product brands. It is the maker of PlusCBD Oil, the leading brand in hemp-derived CBD oil products available online, in health food stores, and in practitioners' offices in the US. The company operates two business segments, including a consumer product division and a drug development division. Its drug development division involves developing and commercializing CBD-based novel therapeutics utilizing CBD, and its consumer product division involves manufacturing, marketing, and selling plant-based CBD products.

Company Headquarters: Ontario, Canada Founded: 2013 Workforce: ~2,100 Company Working: Aphria Inc. is a Canada-based company that provides safe, clean, and pure pharmaceutical-grade cannabis to its customers. The company runs its business through retail and wholesale channels both domestically and internationally. In addition to operating in more than 10 other countries besides Canada, Aphria is a significant supplier of medical cannabis to Germany. Moreover, the company operates as a subsidiary of Tilray, Inc (US) which was acquired in December 2020. It also focuses on the research and development of innovative products and spends a significant amount of revenue on R&D Furthermore, the company is directly present in more than ten countries and has a strong presence in all the established markets such as North America, Europe, Africa, and Australia

Company Headquarters: United States Founded: 1862 Workforce: ~ 27,043 (Global) Company Working: NOV Inc. (NOV or 'the company'), formerly, National OilWell Varco Inc, is a provider of technology and equipment to the oil and gas industry. The company conducts operations in approximately 552 locations across six continents. It owns and leases 137 engineering, sales and administration facilities, 109 service centers and 306 repair and manufacturing facilities. The company serves national and independent service companies, oil and gas operators and contractors in 61 countries worldwide. NOV operates its business through three reportable business segments: Rig Technologies, Wellbore Technologies, and Completion and Production Solutions. The Rig Technologies segment supports the integrated systems and capital equipment, which are used to drill oil and gas wells on land and offshore. It also designs, manufactures and sells land rigs, offshore drilling equipment packages, such as installation and commissioning services, and drilling rig components which mechanize and automate the drilling process and rig functionality. NOV's rig system segment's equipment and technologies include derricks, substructures, and masts; jacking systems; cranes; rotating, and assembly systems, pipe lifting, racking; fluid transfer technologies, such as mud pumps; power transmission systems, including drives and generators; and rig instrumentation and control systems; pressure control equipment, including blowout preventers. It operates manufacturing facilities in New Iberia, Louisiana; Orange, California; Houston, Texas; Dubai, UAE; and Singapore. As of December 2021, it had order backlog of US$2.8 billion. In FY2021, the Rig Technologies segment reported revenue of US$1,739 million, which accounted for 30.7% of the company’s revenue. NOV's Wellbore Technologies segment designs, manufactures, sells and rents various equipment and technologies used for drilling operations. It also offers services that optimize their performance, including solids control and waste management equipment and services, drill pipe, wired pipe, tubular repair, inspection and coating services, fishing and downhole tools, instrumentation and drill bits. The segment serves oil and gas companies and supports oilfield equipment rental companies, drilling contractors and oilfield service companies. It operates manufacturing facilities in Veracruz, Mexico; Houston, Navasota, Conroe, and Cedar Park, Texas; and Dubai, UAE. In FY2021, the Wellbore Technologies segment reported revenue of US$1,959 million, which accounted for 34.6% of the company’s revenue. The Completion and Production Solutions segment integrates technologies for oil and gas production and well completions. It designs, manufactures, and sells equipment and technologies needed for hydraulic fracture stimulation, including pressure pumping trucks, sanders, blenders, hydration units, flow line, manifolds, and injection units. It also manufactures well intervention products, including coiled tubing, coiled tubing units and wireline units and tools; and onshore production systems, including surface transfer, composite pipe, and progressive cavity pumps, and artificial lift systems. In addition, the company supplies offshore production systems, including floating production systems and subsea production technologies. The segment also supports oil and gas companies and service companies. It operates manufacturing facilities in Tulsa, Oklahoma; Houston, and Fort Worth, Texas; Qingdau, Shandong, China; Aberdeenshire, Scotland, UK; Senai, Malaysia; Kalundborg, Denmark; Manchester, England; and Superporto du Acu, Brazil. As of December 2021, it had order backlog of US$1.3 billion. In FY2021, the Completion and Production Solutions segment reported revenue of US$1,963 million, which accounted for 34.7% of the company’s revenue. Geographically, the company classifies its operations into 11 regions: the US, Norway, Singapore, Saudi Arabia, the UK, China, Brazil, Canada, the UAE, South Korea, and Other Countries. In FY2021, the US accounted for 31.9% of the company’s revenue, followed by Norway (6.6%), Singapore (2.6%), Saudi Arabia (5.7%), the UK (3.7%), China (4%), Brazil (5.7%), Canada (3.7%), the UAE (2.4%), South Korea (0.6%), and Other Countries (33.1%).

Company Headquarters: US Founded: 1989 Workforce: 4,700 Company Working: Integra Life Sciences is a leading global medical technology company that specializes in developing, manufacturing, and marketing innovative products and solutions to meet the needs of surgeons, healthcare professionals, and patients worldwide. Integra products are sold in over 130 countries via a direct sales force, distributors, and wholesalers. Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT") are the two reportable business segments in which company manufacture and sell medical technologies and products. The CSS segment, which accounts for two-thirds of our total revenue, consists of market-leading technologies and instrumentation used in a variety of specialties, including neurosurgery, neurocritical care, and otolaryngology.

Company Headquarters: US Founded: 1897 Workforce: 77,000 Company Working: BD (Becton, Dickinson and Company) is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is a leading global medical technology company that is committed to advancing the world of health. The company operates in three main segments: BD Medical, BD Life Sciences, and BD Interventional. Its products and services are used in a wide range of medical settings, including hospitals, clinics, and research laboratories. BD's product portfolio includes a wide range of medical devices and instrument systems, including syringes, needles, catheters, diagnostic tests, and imaging systems. The company is also a leader in the development of healthcare software and data analytics solutions. BD's breast biopsy products are designed to improve the accuracy, speed, and safety of breast biopsy procedures, ultimately leading to better patient outcomes. BD has a significant global presence, with operations in over 190 countries around the world.

Company Headquarters: Basel, Switzerland Founded: 1966 Workforce: ~108,000 Company Working: Novartis International AG (Novartis) is engaged in the production of pharmaceutical drugs. It is a fully integrated life sciences company that provides research, product development, manufacturing, and distribution of products. It is an outstanding worldwide source of regenerative medicine technology, clinical research, education, and training for the constantly evolving healthcare industry. It ranks among the world’s top companies investing in research and development. It carries out research at Novartis locations and partner institutions worldwide: Cambridge, the US; Basel, Switzerland; East Hanover, US; Emeryville, US; and Shanghai, China. Sandoz, a Novartis division, is a global provider of generic pharmaceuticals and biosimilars.

Company Headquarters: Beijing, China Founded: 2015 Workforce: ~300 Company Working: Jacobio Pharmaceuticals Group Co., Ltd. is a biotechnology company that develops and sells autoimmune drugs, cancer drugs, infectious disease drugs, and other products. It has R&D centers in Shanghai, China, and the US. The company manufactures and markets its products throughout China. It is also making partnerships with other players for R&D programs to develop innovative medicines.

Company Headquarters: Washington, US Founded: 1997 Workforce: ~ 2,700 Company Working: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. It offers antibody-drug conjugates (ADCs), including Padcevtm (enfortumab vedotin-ejfv), which is used to treat metastatic urothelial cancers, Adcetris (brentuximab vedotin), which is used to treat Hodgkin's lymphoma, T-cell lymphomas, and CD30-expressing lymphomas. (Tucat) Tukysa. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Additionally, Seagen also licenses its antibody-drug conjugate technology to several biotechnology and pharmaceutical companies. Seagen serves customers on a global scale.

Company Headquarters: New York, US Founded: 1959 Workforce: ~254 Company Working: Misonix, Inc. specializes in the development and commercialization of ultrasonic surgical devices for spinal, neurosurgical, advanced wound care, and general surgery procedures. The company's products enhance clinical outcomes and benefit the entire healthcare system. In addition, the company derives revenue from a number of locations, including the US, the UK, the European Economic Area, Asia and the Asia Pacific, and South America. The company operates in more than 45 countries and is a recognized leader in advanced surgical tools offering unprecedented safety, speed, and precision.

Company Headquarters: New York, US Founded: 1988 Workforce: ~1,200 Company Working: AngioDynamics manufactures disruptive and innovative medical devices. The company provides vital tools to healthcare professionals around the world. It reaches over 50 markets via direct sales and distributors. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. AngioDynamics has operating facilities in Europe, the US, Asia, and Latin America.

Company Headquarters: Vaulx-en-Velin, France Founded: 1979 Workforce: ~ 500 Company Working: EDAP TMS is a pioneer and a market leader in Extracorporeal ShockWave Lithotripsy (ESWL) with the Sonolith range of devices. Its products are marketed through a network of subsidiaries and distribution partners around the globe. It is investing in R&D heavily to maintain and strengthen its level of innovation and research. It also offers three HIFU products such as the Ablatherm, Ablatherm Fusion, and Focal One. Products including lasers, micro-ultrasound equipment, and other medical supplies are sold by its distribution division to support its international activities. The company has operations in France, the US, and other regions.

Company Headquarters: Germany Founded: 1946 Workforce: ~ 1,959 Company Working: Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. Biotest AG develops, manufactures, and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies. Barcelona-based Grifols, a global leader in plasma-derived medicines, today announced the completion of the acquisition of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology.

Company Headquarters: Italy Founded: 2000 Workforce: ~1,050 Company Working: Kedrion S.p.A. develops and distributes plasma-derived medicinal products. The Company produces plasma-derived products for use in treating serious diseases, disorders, and conditions such as hemophilia and immune system deficiencies. Kedrion serves customers worldwide. Kedrion is a biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders, and conditions such as immune system deficiencies and coagulation disorders. The company operates through a fully integrated business model from the collection of plasma in its own centres in the United States to fractionation and production in its manufacturing facilities located in Italy, Hungary, and North America. Headquartered in Castelvecchio Pascoli (Lucca, Italy), Kedrion has approximately 2,800 employees and a commercial presence in 100 countries worldwide.

Company Headquarters: Spain Founded: 1909 Workforce: ~ 4,763 Company Working: Grifols Therapeutics, Inc. operates as a biotherapeutic and biotechnology company. The Company discovers, develops, and produces critical care treatment products for the people with life-threatening disorders. Grifols Therapeutics serves patients, hospitals, pharmacies, and healthcare professionals worldwide. Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing, and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies. Grifols' plasma fractionation capacity is 3.6 million liters of plasma a year and is carried out in the company's two plants located in Parets del Valles (Barcelona) and Los Angeles.

Company Headquarters: UK, Europe Founded: 2012 Workforce: ~ 500 Company Working: Exscientia is a global pharma tech company using patient-first AI, drug discovery, and design enterprise. The company offers its products under the category of the precision target, precision design, precision experiment, and precision medicine. Moreover, the company platform has delivered the first three AI-system to improve clinical outcome in oncology. The company has strong business presence in Europe region.

Company Headquarters: US Founded: 1911 Workforce: ~2,88,300 Company Working: International Business Machines Corporation (IBM) is a technology company. The Company segments include Cloud & Cognitive Software, Global Business Services (GBS), Systems and Global Financing. The Cloud & Cognitive Software Solutions segment delivers integrated and secure cloud, data and artificial intelligence (AI) solutions to its clients. It comprises three business areas: cognitive applications, cloud & data platforms, and transaction processing platforms. The GBS segment provides consulting, business process and application management services. The Global Financing segment is engaged in financing, which is primarily conducted through IBM Credit LLC, and remanufacturing and remarketing. The Systems segment provides clients with infrastructure platforms to help meet the requirements of hybrid multi-cloud and enterprise AI workloads. It also provides telco consulting services and solutions to help communications service providers (CSP) and media on multiple cloud platforms. Geographically, the company classifies its operations into three segments, namely, the Americas, Europe, the Middle East & Africa, and Asia-Pacific.

Health Catalyst, Inc. is a healthcare data-and-analytics technology and services company headquartered in the Salt Lake City metropolitan area. It was incorporated in Delaware in September 2011 under the name HQC Holdings, Inc., and adopted its current name in March 2017, though the operating business traces to 2008 — a lineage the current CEO references directly, describing "eighteen years working with health systems" on the Q2 2026 earnings call (Q2 2026 earnings release, 6 Aug 2026). The company completed its initial public offering in July 2019. **Positioning statement (150 words).** Health Catalyst occupies the healthcare-specific layer of the provider data stack: it ingests, normalises and governs clinical, claims, financial and operational data for health systems, then sells analytics applications and human expertise on top of it. Its distinctive asset is not infrastructure — management now openly concedes the data-platform layer has commoditised against Databricks, Snowflake and Microsoft — but a proprietary corpus of measured improvement outcomes accumulated over 18 years and more than 2,000 documented, client-verified improvements. The 2026 strategy under new CEO Ben Albert reframes the company as a "healthcare intelligence" business: an AI-enabled improvement layer that quantifies, prioritises and sequences cost, clinical-quality, ambulatory-growth and consumer interventions. Execution risk is acute. The company is simultaneously migrating clients off its legacy DOS platform, restructuring its cost base, having divested its most profitable software unit, and carrying an accumulated deficit above USD 1.5 billion against a market capitalisation near USD 135 million. --- ### 2.1 The company's own description The FY2025 Form 10-K opens with an unchanged framing: *"We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data and analytics platform, software applications, and expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data-informed."* The company organises its self-description around three components: (i) the Ignite Data & Analytics Platform, a healthcare-specific, cloud-based, open and self-service ecosystem for analytics, application development and interoperability; (ii) Applications, software analytics products built on Ignite across five focus areas — Clinical Improvement, Revenue & Cost Improvement, Ambulatory Operations, Measures & Registries, and Data & Analytics; and (iii) Expertise, a services organisation of data engineers, data scientists, clinicians and healthcare administrators delivering implementation, analytics, abstraction, cost-accounting and Tech-Enabled Managed Services (TEMS). The company describes its operating philosophy through the "Health Catalyst Flywheel": team-member engagement drives quality of work, which drives measurable client improvement, which drives client trust, renewal, expansion and referral, which drives predictable financial performance. This construct is not decorative — it is referenced in the executive compensation design disclosed in the 10-K/A, where annual bonus outcomes for all team members are tied to client outcomes, growth and Adjusted EBITDA. By August 2026 the company's boilerplate had been rewritten materially. The Q2 2026 release describes Health Catalyst as *"a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance,"* backed by *"deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes."* The shift from "data and analytics technology and services" to "healthcare intelligence" is the clearest single marker of the strategy reset. ### 2.2 Independent characterisation Health Catalyst is, in economic terms, a hybrid of three businesses that have historically been bundled and are now being deliberately unbundled. The first is a healthcare data-platform business (formerly DOS, now Ignite) sold on multi-year subscription. This is the anchor relationship: it creates switching costs, it is the surface on which applications are sold, and it is the layer under most competitive pressure. Management's Q1 2026 admission that "healthcare data infrastructure has increasingly commoditized" is a significant concession from a company whose original thesis was that healthcare data warehousing required purpose-built architecture. The second is a portfolio of point-solution applications, largely assembled through twelve acquisitions since 2018 — patient engagement (Twistle, Upfront), care orchestration (Lumeon), oncology (Carevive), registries (ARMUS, CRStar/ERS), measures (MeasureAble/Able Health), cost accounting (PowerCosting), labour management (PowerLabor), interoperability (Ninja Universe/KPI Ninja), cybersecurity (Intraprise), and — until 31 July 2026 — mid-revenue-cycle (Vitalware). These applications carry higher gross margins than services and are the intended vehicle for AI monetisation. The third is a professional services and managed-services organisation. This is the structurally problematic segment: FY2025 adjusted gross margin of 18.3% and GAAP gross margin of 12.8%, on revenue that declined 8% year over year. Management now guides this business to roughly USD 55 million annually exiting 2026, versus USD 111.7 million in FY2024 — a deliberate contraction of nearly half. **Revenue model mix.** The company reports two revenue lines only: Technology revenue is predominantly recurring subscription; professional services is a mix of recurring managed services (TEMS) and project-based, non-recurring engagement revenue. The company explicitly flags fluctuation in "project-based, non-recurring revenue" as a principal risk in every earnings release reviewed. **Value-chain position.** Health Catalyst sits between the EHR system of record (Epic, Oracle Health) and the health system's executive decision-making layer. It does not own the transactional workflow; it owns the analytic abstraction of it. This is simultaneously its defensibility (EHR vendors historically underinvested in cross-source analytics) and its vulnerability (EHR vendors are now investing heavily, and the 10-K names "the increasing market share of EHR companies in data analytic services, patient engagement and other parts of our Solution" as a specific cause of contract termination risk). **Customer types and end-markets.** Academic medical centres, integrated delivery networks, community hospitals, large physician practices, Accountable Care Organizations, health information exchanges, health insurers, life-science organisations, healthcare technology vendors (for cybersecurity) and other risk-bearing entities. Named clients in the FY2025 10-K: Allina Health, AlohaCare, Baylor Scott & White Health, Carle Health, Children's Hospital of Orange County, Community Health Network, Contexture, INTEGRIS Health, Lifepoint Health, Mass General Brigham, MultiCare, Queen's Health System, Temple University Health System, UnityPoint Health, UPMC. No client represented more than 10% of total revenue in FY2025, FY2024 or FY2023 (10-K FY2025). ---

Company Headquarters: New York, US Founded: 1999 Workforce: ~40,000 Company Working: ExlService Holdings Inc (ExlService) is a business process management service provider. The company offers domain expertise, operations management, data analytics, digital technology platforms, and various services such as insurance, healthcare, and banking solutions. It also provides financial, travel, transportation, and logistics solutions, finance and accounting solutions, consulting services, analytics solutions, and digital solutions. It serves the insurance, healthcare, travel and leisure, transportation and logistics, banking and financial, and utility industries. It has a business presence in the US, Europe, Latin America, South Africa, Australia, and Asia.

Company Headquarters: Illinois, US ‎ Founded: 1986 Workforce: ~8,400 Company Working: Allscripts Healthcare, LLC (Allscripts) is a leader in healthcare information technology solutions, providing advanced clinical, financial, and operational results to clients. The company offers comprehensive healthcare industry solutions designed to help clients improve the quality and efficiency of healthcare services by providing electronic health records (EHR), financial management, population health management, and precise medicine/consumer solutions. The company has a global presence across 7 countries: the US, Australia, India, Canada, Singapore, Israel, and the UK.

Company Headquarters: Germany Founded: 2003 Workforce: The company had total more than 11,000 employees. Company Working: Symrise is a global supplier of fragrances and flavorings, cosmetic active ingredients and raw materials, function ingredients and products solutions for food production based on natural base materials. The company operates through two divisions: Taste, Nutrition & Health and Scent & Care. It develops. produces, and sells approximately 34,000 fragrances and flavors and cosmetic ingredients based on around 10,000 mostly natural raw materials. Symrise sells its products in more than 150 countries to makers of fine fragrances, cosmetics, hair and body care products, detergents, food and beverages, and pharmaceuticals. It has development centers in Germany, Brazil, China, France, Singapore, the US, and in some other countries. Symrise was formed in 2003 when Dragoco and Haarmann & Reimer merged. The company generates the majority of its sales in Europe, Africa, and the Middle East.

Company Headquarters: Illinois, United States Founded: 1902 Workforce: ~42,000 Company Working: Archer-Daniels-Midland Company (ADM) is one of the leading manufacturers and suppliers of various food & beverage ingredients and agricultural products. The product portfolio of the company comprises diversified products ranging from natural flavors and colors to vegetable oil, sweeteners to flour, animal feed, and biofuels among others catering to human nutrition, animal nutrition, pet nutrition, and industrial bio solutions industry. Ag services and oilseeds, carbohydrate solutions, and nutrition are the three business operating segments. The Ag services and oilseeds segment is dedicated to the operations and processing of agricultural raw materials and oilseeds which are marketed as ingredients for other industrial production. The Carbohydrate Solutions segment markets various sweeteners and other ingredients for animal feed manufacturing and the food & beverage industry. Apart from its production, the company has around half of the equity interest share in a sweeteners and starch company, Aston Foods and Food Ingredients, Russia. The nutrition segment comprises the production of hydrocolloids, emulsifiers, natural colors, polyols, enzymes, prebiotics & probiotics, plant-based proteins, and several other similar specialty ingredients. The company is also involved in the Investment and Insurance business through ADM Investors Services, Inc., Agri national Insurance companies, and allied subsidiaries. The company executes its production and research & development through different plants, and innovative centers located in different regions including eight innovation centers, twenty-five processing plants, and fifty-nine procurement centers in Asia-Pacific. Further, it has five innovation centers, thirty-nine processing plants, and sixty-nine procurement centers in South America.

Company Headquarters: US Founded: 1996 Workforce: ~11,300 Company Working: Tupperware is a leading manufacturer of premium and innovative product offerings. Its product range comprises customer-oriented storage and serving solutions focused on kitchenware and other domestic applications that mainly comprise food storage, serving & preparation, containers, and toys & gifts. The company operates in more than 80 countries across Europe, the Middle East & Africa, Asia-Pacific, North America, and South America. Tupperware has about 2,000 distributors, 113,200 managers (comprising directors and team leaders), and 2.9 million sales team members across the globe.

Company Headquarters: US Founded: 1991 Workforce: ~18,775 Company Working: Graphic Packaging Holding Company is a leading provider of consumer goods packaging with sustainable and paper-based packaging solutions for end-use verticals, including food, beverage, food service, and commercial product manufacturers. The company is one of the largest producers of folding cartons and fiber-based food service products in the US and Europe. It has divided its operations into three segments: paperboard mills, America's Paperboard Packaging, and Europe Paperboard Packaging. The company offers food service packaging with a broad selection of the highest-quality single-use beverage cups and containers. It owns and operates over 90 manufacturing facilities globally across 15 different countries.

Company Headquarters: US Founded: 1892 Workforce: ~33,000 Company Working: Crown Holdings Incorporated is engaged in designing, manufacturing, and marketing packaging products and equipment for domestic and commercial products. The company's packaging products include steel and aluminum cans for packaging food items, beverages, and household products. It manufactures various aluminum and food cans to suit established and emerging beverage applications, drinking occasions, distribution channels, and others. It owns and operates over 236 manufacturing facilities spread across 47 countries worldwide.

Company Headquarters: US Founded: 1967 Workforce: ~47,000 Company Working: Berry Plastics Corporation (Berry) designs and manufactures technologically innovative, rigid, flexible, and non-woven packaging products across the globe. The company operates through three segments: consumer packaging international, consumer packaging in North America, engineered materials, health hygiene, and specialties. Consumer packaging North America manufactures lightweight polypropylene cups and lids for hot and cold beverages, mono-material cup & lid packaging solutions, closures & over cups that are resistant to children's activities providing continuous-thread, tamper-proof closures, and aerosol cans, bottles, and prescription vials, among others. Under its engineered materials segment, Berry offers food and consumer films for fresh bakery products, tortillas, deli, and frozen vegetables. Additionally, the company manufactures barrier films for cereals, cookies, crackers, and dry mix packages. The company invested over USD 50 million in 2019 for research & development. In 2017, it was renamed from Berry Plastics Group, Inc. to Berry Global, Inc. It operates through offices in over 295 locations and serves its customers across the globe.

Company Headquarters: Australia Founded: 1860 Workforce: ~47,000 Company Working: Amcor plc (Amcor) is a leading packaging company that develops and manufactures flexible and rigid packaging solutions for applications in the food & beverages, pharmaceuticals, healthcare, home & personal care industries. The company operates through two segments, namely, flexibles and rigid packaging. Furthermore, the company also offers high-barrier foils and films through its subsidiary—Bemis Company, Inc. Amcor operates in more than 40 countries and has approximately 230 manufacturing sites worldwide. It has a presence across more than 40 countries across North America, Europe, Asia-Pacific, and Latin America. Bemis Company, Inc, Amcor Flexibles (Dandenong) Pty Ltd, Amcor Packaging (Asia) Pty Ltd, Amcor Flexibles (Port Melbourne) Pty Ltd, and Amcor Flexibles Group Pty Ltd are some of its subsidiaries.

Company Headquarters: Osaka, Japan Founded: 1918 Workforce: ~1,009 Company Working: Nitta Gelatin Inc. (Nitta Gelatin) is a leading gelatin and collagen peptide manufacturer and distributor with manufacturing facilities located in Japan, India, North America, Vietnam, and others. The company also manufactures stabilizers, edible gelling agents, and other food materials. Though the company has consolidated all its business segments into a single collagen business entity for financial reporting purposes, the four broad market segments the company is currently operating comprise of gelatin, peptide, biomedical and food material business. The consolidated group includes Nitta Gelatin NA Inc. (USA), Nitta Gelatin Canada, Inc., Nitta Gelatin USA, Inc., Vyse Gelatin, LLC, Nitta Gelatin Holding, Inc., Nitta Gelatin India Ltd., Bamni Proteins Ltd., Shanghai Nitta Gelatin Co., Ltd., Nitta Gelatin Vietnam Co., Ltd., and Hikone Gelatin Inc. The key raw materials used in the production of gelatin are porcine, fish, and bovine.